Table 2.
Characteristics of the Lung Function and Asthma Therapy in the Cohort at First Visit in the Management of Asthma During Pregnancy Program
| Characteristics | Cohort | Cases (Asthma + Perennial Allergy) | Controls (Asthma + Season and No Allergy) | p-value |
|---|---|---|---|---|
| Subjects (n) | 932 | 544 | 388 | |
| FeNO > 50 ppb | 43 (4.6) | 28 (5.1) | 15 (3.9) | 0.360 |
| Lung Function | ||||
| FEV1 < 80% pred. | 150 (16.1) | 81 (14.9) | 69 (17.8) | 0.237 |
| FEV1/FVC < 0.7 | 46 (4.9) | 27 (5.0) | 19 (4.9) | 0.963 |
| Asthma Therapy | ||||
| Inhaled corticosteroids (ICS) | 598 (64.2) | 359 (66.0) | 239 (61.6) | 0.168 |
| Low dose* | 438 (47) | 268 (49.3) | 170 (43.8) | 0.100 |
| Medium dose* | 153 (16.4) | 90 (16.3) | 63 (16.2) | 0.901 |
| High dose* | 7 (0.8) | 5 (0.9) | 2 (0.5) | 0.488 |
| Long-acting beta-2 agonist in combination with ICS | 17 (1.8) | 12 (2.2) | 5 (1.3) | 0.308 |
| Leukotriene receptor antagonist | 8 (0.9) | 4 (0.7) | 4 (1.0) | 0.631 |
| Oral corticosteroids | 1 (0.1) | 0 | 1 (0.3) | 0.994 |
Notes: Data are given as numbers with percentages in brackets. *Beclometasone equivalent doses.